Research programme: biosimilars - Insmed/Merck

Drug Profile

Research programme: biosimilars - Insmed/Merck

Alternative Names: Epoetin alfa bisomilar - Merck; INS-21; INS-22; Interferon beta-1b biosimilar - Merck

Latest Information Update: 29 Aug 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Insmed
  • Class Interferons; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Anaemia; Multiple sclerosis

Most Recent Events

  • 29 Aug 2013 No development reported - Preclinical for Anaemia in USA (SC)
  • 29 Aug 2013 No development reported - Preclinical for Multiple sclerosis in USA (SC)
  • 01 Jan 2006 Preclinical trials in Anaemia in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top